Mohamed E. Elrggal
@M_Elraggal
Followers
2K
Following
23K
Media
212
Statuses
4K
Adult Nephrologist, #NSMC Faculty, Learner, Father
Alexandria, Egypt
Joined January 2013
RT @drkeithsiau: Large volume paracentesis - check out the total volume drained at the end!.
0
342
0
RT @mvaduganathan: Just 5 years ago, HFpEF was described as the “stepchild” of HF with no approved therapies. Today, there are 5 US FDA th….
0
159
0
Our recent review.
Need to brush up on Sparsentan, a DEARA for IgA Nephropathy? Check out our recent review. Including a VA from @NephJC. @edgarvlermamd @AnnaGaddy .
0
0
2
Read this piece from the ERAKI working group at the.@NDTsocial regarding the results of the DEFENDER trial published last August @JAMA_current .
0
3
5
RT @edgarvlermamd: Sparsentan: a dual endothelin and angiotensin II receptor antagonist (DEARA) approved for IgA nephropathy (IgAN) ca 2025….
0
8
0
RT @kdjhaveri: Kidney News July 2025 @asnpublications Clinical Practice Guidelines for Genetic Testing in ADPKD.Neera K. Dahl @pranavgarime….
0
49
0
RT @hjanders_hans: Now open access in the June edition of @NDTsocial. Disease-modifying anti-nephropathic drugs (DMANDs)—a definition propo….
0
20
0
RT @ChengHsuanTsai: Low-renin hypertension despite the use of ACE inhibitors or ARBs is almost certainly a form of primary aldosteronism.….
0
12
0
RT @kdjhaveri: May 2025 @asnpublications Kidney News Preeclampsia and Rare Genetic Variants in the Terminal Complem….
0
8
0
RT @NDTsocial: Tailored management strategies for IgA nephropathy based on clinical presentations. 🆓 This Review pr….
0
35
0
When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases.An amazing article from the high impact articles published @NDTsocial @hjanders_hans.
academic.oup.com
ABSTRACT. Kidney disease frequently coexists with cardiovascular (CV) diseases, and this dual presence significantly amplifies the risk of adverse clinical
0
7
19
RT @ISNkidneycare: Looking to improve kidney care in your region? 🌍 The ISN offers practical #OpenAccess toolkits for health professionals,….
0
8
0
RT @ISNkidneycare: 7️⃣ ISN-ACT Clinical Trials Toolkit: A global resource for nephrologists and researchers of all experience levels, offer….
0
8
0
RT @kdjhaveri: Podcast--Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury @ShrutiGkidney.
edhub.ama-assn.org
Interview with Shruti Gupta, MD, MPH, author of Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. Hosted by Vivek Subbiah, MD.
0
6
0
RT @DoctorGates: A great group effort on describing the latest large trial landscape for treatment in diabetic kidney disease.
0
1
0
RT @edgarvlermamd: Diabetic Kidney Disease (DKD) ca. 2025 from @ElsevierConnect @AnnaGaddy @M_Elraggal @HecmagsMD @DoctorGates .#Nephpearls….
0
56
0
I am totally with you.
As a @NephMadness #BlueRibbonPanel member, IMO only one #BlueRibbonFail so far: HDF v Incr- HD with HDF barely losing 4-5. Nothing has impacted RRT survival in 30 yr, HDF can. Time to remove the real toxins. The kidney is convective, lets HDF convectively. Huge BRP fail.
0
0
1
